Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Interethnic PK Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects that are scheduled for bariatric surgery.~* Subjects that are able and willing to donate surplus intestinal tissue.~* Subjects with solute carrier organic anion transporter \*1 (SLCO1B1) and breast cancer resistant protein (BCRP) 421CC genotypes.~* White/Caucasian/European and Asian/East Asian heritage individuals, male or female, 18 years of age or older.~* BMI between 30-55 kg/m2~* Be able to read, speak, and understand English(UCSF) and Chinese(Taiwan).~* Subjects capable of providing informed consent and completing the requirements of the study.~Exclusion Criteria:~* Subjects with active liver and kidney problems, severe cardiovascular diseases, type I diabetes, advanced pulmonary disease, and cancers.~* Subjects on chronic prescription or over the counter medication that have previously been reported to exhibit drug-drug interactions with rosuvastatin and cannot be stopped two weeks prior to and during the study, including gemfibrozil, cyclosporine, atazanavir, lopinavir and ritonavir.~* Subjects incapable of multiple blood draws (HCT \< 30mg/dL).~* Subjects with a history of rhabdomyolysis.~* Subjects with a history of drug-related myalgias.~* Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias.~* Subjects with a history of GI bleed or peptic ulcer disease.~* Subjects with a recent history of trauma.~* Subjects who smoke tobacco or have ongoing alcohol or illegal drug use.~* Subjects who are pregnant, lactating, or trying to conceive during the study period.~* Subjects allergic to rosuvastatin or any known component of the medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Asians (Type: EXPERIMENTAL): Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
- Caucasians (Type: EXPERIMENTAL): Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor

Based on this trial design, predict the completion outcome and termination type (if applicable).